pharmaceutical and medical preparations for the treatment of diseases, illnesses and ailments in humans and animals, namely: neoplasms; neurological d Read More

Classification Information

Class [005]
Pharmaceutical and medical preparations for the treatment of diseases, illnesses and ailments in humans and animals, namely: neoplasms; neurological diseases, namely Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia with Lewy bodies, Pick's disease, frontotemporal dementia, argyrophilic disease, progressive supranuclear palsy, fronto-temporal dementia, parkinsonism linked to chromosome 17, disinhibition-dementia-parkinsonism-amyotrophy complex, pallido-ponto-nigral degeneration, Guam-ALS syndrome; pallido-nigro-luysian degeneration, cortico-basal degeneration, mild cognitive impairment (MCI), multiple system atrophy, drug-induced parkinsonism, and pure autonomic failure; psychiatric diseases, namely, schizophrenia, mood disorders, anxiety disorders, and cognitive disorders; neurological disorders, namely, mild cognitive impairment, tauopathies, and synucleinopathies; cancer; methemoglobinemia; viral diseases, namely herpes, hepatitis, acquired immune deficiency syndrome, and West Nile virus infection; and protozoal diseases, namely malaria, visceral leishmaniasis; African sleeping sickness, toxoplasmosis, giardiasis, and Chagas' disease; pharmaceutical and medical preparations for the treatment of diseases, illnesses and ailments in humans and animals, namely for use in oncology; and pharmaceutical and medical preparations for the treatment of diseases, illnesses and ailments in humans and animals, namely antibiotics, antivirals, and antiprotozoals; chemical preparations for medical and pharmaceutical purposes, namely for the treatment of diseases, illnesses and ailments in humans and animals, namely: neoplasms; neurological diseases, namely Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, dementia with Lewy bodies, Pick's disease, frontotemporal dementia, argyrophilic disease, progressive supranuclear palsy, fronto-temporal dementia, parkinsonism linked to chromosome 17, disinhibition-dementia-parkinsonism-amyotrophy complex, pallido-ponto-nigral degeneration, Guam-ALS syndrome; pallido-nigro-luysian degeneration, cortico-basal degeneration, mild cognitive impairment (MCI), multiple system atrophy, drug-induced parkinsonism, and pure autonomic failure; psychiatric diseases, namely, schizophrenia, mood disorders, anxiety disorders, and cognitive disorders; neurological disorders, namely, mild cognitive impairment, tauopathies, and synucleinopathies; cancer; methemoglobinemia; viral diseases, namely herpes, hepatitis, acquired immune deficiency syndrome, and West Nile virus infection; and protozoal diseases, namely malaria, visceral leishmaniasis; African sleeping sickness, toxoplasmosis, giardiasis, and Chagas' disease; chemical preparations for medical and pharmaceutical purposes, namely for the treatment of diseases, illnesses and ailments in humans and animals, namely for use in oncology; and chemical preparations for medical and pharmaceutical purposes, namely for the treatment of diseases, illnesses and ailments in humans and animals, namely antibiotics, antivirals, and antiprotozoals.

Classification kind code

Class [042]
Medical, biological, biotechnological, genetic and pharmaceutical research services; research, development and design of drugs and medicine; laboratory and medical laboratory research and development services; preparation of reports of scientific and medical research concerning medicines, pharmaceuticals, genetics, biology, biotechnology and drugs; development and design of prognostic and diagnostic tools; providing research consultation and information in the fields of medical, pharmaceutical, genetic, biological, drugs, clinical, statistical and biotechnological research.

Classification kind code

Mark Details

Serial Number

1760677

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 50 on 24^th Aug 2018	Allowed
Submitted for opposition 42 on 09^th May 2018	Advertised
Submitted for opposition 26 on 19^th Apr 2018	Approved
Submitted for opposition 27 on 27^th Feb 2018	Approval Notice Sent
Submitted for opposition 15 on 03^rd Feb 2017	Correspondence Created
Submitted for opposition 22 on 27^th May 2016	Search Recorded
Submitted for opposition 20 on 27^th May 2016	Examiner's First Report
Submitted for opposition 31 on 30^th Dec 2015	Formalized
Submitted for opposition 1 on 22^nd Dec 2015	Created
Submitted for opposition 30 on 21^st Dec 2015	Filed